Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody — broad-phenotype biologic

Tezepelumab

Brand names: Tezspire (210 mg/1.91 mL prefilled syringe)

Tezepelumab is a human monoclonal antibody given by subcutaneous injection that targets thymic stromal lymphopoietin (TSLP), used as add-on maintenance therapy for severe asthma.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds TSLP, an upstream epithelial cytokine, and blocks its interaction with its receptor, interrupting multiple downstream inflammatory pathways irrespective of asthma phenotype.

Prescribing in practice

  • It is an add-on preventer for severe asthma and must not be used to treat acute bronchospasm or exacerbations; usual inhaled therapy must continue.
  • Hypersensitivity reactions can occur, and treatment is initiated within specialist severe-asthma services per NICE guidance.
  • Treat any pre-existing helminth infection before starting, and avoid administering live vaccines during treatment without specialist advice.

Monitoring

Monitor asthma control and exacerbation frequency, and observe for hypersensitivity reactions after administration.

Counselling the patient

  • This injection helps prevent asthma attacks over time and is not a rescue treatment.
  • Keep taking your usual inhalers and reliever.
  • Report any rash, swelling or breathing difficulty after a dose.

Evidence & guidelines

The NAVIGATOR trial showed that tezepelumab reduces exacerbations across a broad severe-asthma population, supporting NICE-recommended add-on use.

Reference: NICE TA954 (2024); NAVIGATOR Trial (Menzies-Gow et al, NEJM 2021); SOURCE Trial; GINA 2024; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways